Navigation Links
Cleveland Clinic identifies mechanism in Alzheimer's-related memory loss

Sunday, Jan. 19, 2014, Cleveland: Cleveland Clinic researchers have identified a protein in the brain that plays a critical role in the memory loss seen in Alzheimer's patients, according to a study to be published in the journal Nature Neuroscience and posted online today.

The protein Neuroligin-1 (NLGN1) is known to be involved in memory formation; this is the first time it's been linked to amyloid-associated memory loss.

In Alzheimer's disease, amyloid beta proteins accumulate in the brains of Alzheimer's patients and induce inflammation. This inflammation leads to certain gene modifications that interrupt the functioning of synapses in the brain, leading to memory loss.

Using animal models, Cleveland Clinic researchers have discovered that during this neuroinflammatory process, the epigenetic modification of NLGN1 disrupts the synaptic network in the brain, which is responsible for developing and maintaining memories. Destroying this network can lead to the type of memory loss seen in Alzheimer's patients.

"Alzheimer's is a challenging disease that researchers have been approaching from all angles," said Mohamed Naguib, M.D., the Cleveland Clinic physician who lead the study. "This discovery could provide us with a new approach for preventing and treating Alzheimer's disease."

Previous studies from this group of researchers have also identified a novel compound called MDA7, which can potentially stop the neuroinflammatory process that leads to the modification of NLGN1. Treatment with the compound restored cognition, memory and synaptic plasticity a key neurological foundation of learning and memory in an animal model. Significant preliminary work for the first-in-man study has been completed for MDA7 including in-vitro studies and preliminary clinical toxicology and pharmacokinetic work. The Cleveland Clinic plans to initiate Phase I human studies on the safety of this class of compounds in the near future.

Alzheimer's disease is an irreversible, fatal brain disease that slowly destroys memory and thinking skills. About 5 million people in the United States have Alzheimer's disease. With the aging of the population, and without successful treatment, there will be 16 million Americans and 106 million people worldwide with Alzheimer's by 2050, according to the 2011 Alzheimer's Disease Facts and Figures report from the Alzheimer's Association.


Contact: Andrea Pacetti
Cleveland Clinic

Related biology news :

1. 2 Cleveland Clinic researchers honored for contribution to science
2. Cleveland Clinics 2013 Obesity Summit explores causes, prevention and treatment of obesity
3. Cleveland Clinic research shows gut bacteria byproduct predicts heart attack and stroke
4. Cleveland Clinic researchers discover new link between heart disease and red meat
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
7. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
8. MedNet Solutions Announces Latest Release Of Its Innovative iMedNet EDC eClinical Solution
9. Most clinical studies on vitamins flawed by poor methodology
10. Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy
11. Online tool aids clinicians efforts to treat injured workers
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Fingerprint Sensors - Technology and Patent Infringement Risk Analysis" ... --> --> Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:11/19/2015)... 19, 2015  Although some 350 companies are actively ... a few companies, according to Kalorama Information. These include Roche ... the market share of the 6.1 billion-dollar molecular testing ... Market for Molecular Diagnostic s .    ... still controlled by one company and only a handful ...
(Date:11/17/2015)... , November 17, 2015 Paris ...   --> Paris from 17 th ... DERMALOG, the biometrics innovation leader, has invented the first combined ... on the same scanning surface. Until now two different scanners ... one scanner can capture both on the same surface. ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... Dec. 01, 2015 ... of the "2016 Europe Cell Surface ... Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, ... offering. --> ) has ... Europe Cell Surface Markers: Country Volume and ...
(Date:12/1/2015)...  Symic, a clinical-stage biotherapeutics company developing multiple compounds ... announced that it has secured $25 million in a ... its lead candidates SB-030 and SB-061. The financing was ... all existing major investors, as well as several new ... by Symic to over $43 million since being founded ...
(Date:12/1/2015)... DUBLIN , December 1, 2015 /PRNewswire/ ... the addition of the  "2016 U.K. Virology ... Segment Forecasts for 100 Tests, Supplier Shares ... Opportunities"  report to their offering.  --> ... of the  "2016 U.K. Virology and Bacteriology ...
(Date:11/30/2015)... Dec. 1, 2015  An interventional radiology technique shows promise ... preliminary results of a study being presented today at the ... America (RSNA). --> ... decades by interventional radiologists as a way to stop bleeding ... as a means of treating obesity is new. ...
Breaking Biology Technology: